Antibody-epitope conjugates deliver immunogenic T-cell epitopes more efficiently when close to cell surfaces

References

• Sefrin JP, Hillringhaus L, Mundigl O, Mann K, Ziegler-Landesberger D, Seul H, Tabares G, Knoblauch D, Leinenbach A, Friligou I. et al. Sensitization of tumors for attack by virus-specific CD8+ T-Cells through antibody-mediated delivery of immunogenic T-Cell epitopes. Front Immunol. 2019;10:1962. doi:10.3389/fimmu.2019.01962.
   PubMed Web of Science ®Google Scholar
• Millar DG, Ramjiawan RR, Kawaguchi K, Gupta N, Chen J, Zhang S, Nojiri T, Ho WW, Aoki S, Jung K. et al. Antibody-mediated delivery of viral epitopes to tumors harnesses CMV-specific T cells for cancer therapy. Nat Biotechnol. 2020;38(4):420–9. doi:10.1038/s41587-019-0404-8.
   PubMed Web of Science ®Google Scholar
• Yan C, Yang Q, Zhang S, Millar DG, Alpert EJ, Do D, Veloso A, Brunson DC, Drapkin BJ, Stanzione M. et al. Single-cell imaging of T cell immunotherapy responses in vivo. J Exp Med. 2021;218(10): doi:10.1084/jem.20210314.
   Web of Science ®Google Scholar
• Jung K, Son M-J, Lee S-Y, Kim J-A, Ko D-H, Yoo S, Kim C-H, Kim Y-S. Antibody-mediated delivery of a viral MHC-I epitope into the cytosol of target tumor cells repurposes virus-specific CD8(+) T cells for cancer immunotherapy. Mol Cancer. 2022;21(1):102. doi:10.1186/s12943-022-01574-0.
   PubMed Web of Science ®Google Scholar
• Zhang S, Yan C, Millar DG, Yang Q, Heather JM, Langenbucher A, Morton LT, Sepulveda S, Alpert E, Whelton LR. et al. Antibody-peptide epitope conjugates for personalized cancer therapy. Cancer Res. 2022;82(5):773–784. doi:10.1158/0008-5472.CAN-21-2200.
   PubMed Web of Science ®Google Scholar
• van der Wulp W, Gram AM, Bleijlevens B, Hagedoorn RS, Araman C, Kim RQ, Drijfhout JW, Parren PWHI, Hibbert RG, Hoeben RC. et al. Comparison of methods generating antibody-epitope conjugates for targeting cancer with virus-specific T cells. Front Immunol. 2023;14:1183914. doi:10.3389/fimmu.2023.1183914.
   PubMed Web of Science ®Google Scholar
• Klenerman P, Oxenius A. T cell responses to cytomegalovirus. Nat Rev Immunol. 2016;16(6):367–77. doi:10.1038/nri.2016.38.
   PubMed Web of Science ®Google Scholar
• Hislop AD, Taylor GS, Sauce D, Rickinson AB. Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu Rev Immunol. 2007;25(1):587–617. doi:10.1146/annurev.immunol.25.022106.141553.
   PubMedGoogle Scholar
• Cicin-Sain L, Arens R. Exhaustion and inflation at antipodes of T cell responses to chronic virus infection. Trends Microbiol. 2018;26(6):498–509. doi:10.1016/j.tim.2017.11.012.
   PubMed Web of Science ®Google Scholar
• Yewdell JW, Bennink JR. Immunodominance in major histocompatibility complex class I–restricted T lymphocyte responses. Annu Rev Immunol. 1999;17(1):51–88. doi:10.1146/annurev.immunol.17.1.51.
   PubMed Web of Science ®Google Scholar
• Schneidt V, Ilecka M, Dreger P, van Zyl DG, Fink S, Mautner J, Delecluse H-J. Antibodies conjugated with viral antigens elicit a cytotoxic T cell response against primary CLL ex vivo. Leukemia. 2019;33(1):88–98. doi:10.1038/s41375-018-0160-7.
   PubMed Web of Science ®Google Scholar
• van der Wulp W, Remst DFG, Kester MGD, Hagedoorn RS, Parren PWHI, van Kasteren SI, Schuurman J, Hoeben RC, Ressing ME, Bleijlevens B. et al. Antibody-mediated delivery of viral epitopes to redirect EBV-specific CD8(+) T-cell immunity towards cancer cells. Cancer Gene Ther. 2024;31(1):58–68. doi:10.1038/s41417-023-00681-4.
   PubMed Web of Science ®Google Scholar
• Vink T, Oudshoorn-Dickmann M, Roza M, Reitsma J-J, de Jong RN. A simple, robust and highly efficient transient expression system for producing antibodies. Methods. 2014;65(1):5–10. doi:10.1016/j.ymeth.2013.07.018.
   PubMed Web of Science ®Google Scholar
• Labrijn AF, Meesters JI, de Goeij BECG, van den Bremer ETJ, Neijssen J, van Kampen MD, Strumane K, Verploegen S, Kundu A, Gramer MJ. et al. Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange. Proc Natl Acad Sci. 2013;110(13):5145–5150. doi:10.1073/pnas.1220145110.
   PubMed Web of Science ®Google Scholar
• Desnoyers LR, Vasiljeva O, Richardson JH, Yang A, Menendez EEM, Liang TW, Wong C, Bessette PH, Kamath K, Moore SJ. et al. Tumor-specific activation of an EGFR-targeting probody enhances therapeutic index. Sci Transl Med. 2013;5(207):207ra144. doi:10.1126/scitranslmed.3006682.
   PubMed Web of Science ®Google Scholar
• Cuburu N, Bialkowski L, Pontejo SM, Sethi SK, Bell ATF, Kim R, Thompson CD, Lowy DR, Schiller JT. Harnessing anti-cytomegalovirus immunity for local immunotherapy against solid tumors. Proc Natl Acad Sci U S A. 2022;119(26):e2116738119. doi:10.1073/pnas.2116738119.
   PubMed Web of Science ®Google Scholar
• Rosato PC, Wijeyesinghe S, Stolley JM, Nelson CE, Davis RL, Manlove LS, Pennell CA, Blazar BR, Chen CC, Geller MA. et al. Virus-specific memory T cells populate tumors and can be repurposed for tumor immunotherapy. Nat Commun. 2019;10(1):567. doi:10.1038/s41467-019-08534-1.
   PubMedGoogle Scholar
• Gulley JL, Madan RA, Pachynski R, Mulders P, Sheikh NA, Trager J, Drake CG. Role of antigen spread and distinctive characteristics of immunotherapy in cancer treatment. J Natl Cancer Inst. 2017;109(4):109(4. doi:10.1093/jnci/djw261.
   Google Scholar
• Poreba M. Protease-activated prodrugs: strategies, challenges, and future directions. FEBS J. 2020;287(10):1936–1969. doi:10.1111/febs.15227.
   PubMed Web of Science ®Google Scholar
• Fu Z, Li S, Han S, Shi C, Zhang Y. Antibody drug conjugate: the “biological missile” for targeted cancer therapy. Signal Transduct Target Ther. 2022;7(1):93. doi:10.1038/s41392-022-00947-7.
   PubMed Web of Science ®Google Scholar
• Wong KR, Menendez E, Craik CS, Kavanaugh WM, Vasiljeva O. In vivo imaging of protease activity by probody therapeutic activation. Biochimie. 2016;122:62–67. doi:10.1016/j.biochi.2015.11.003.
   PubMed Web of Science ®Google Scholar
• Harmand TJ, Bousbaine D, Chan A, Zhang X, Liu DR, Tam JP, Ploegh HL. One-pot dual labeling of IgG 1 and preparation of C-to-C fusion proteins through a combination of sortase a and butelase 1. Bioconjug Chem. 2018;29(10):3245–49. doi:10.1021/acs.bioconjchem.8b00563.
   PubMed Web of Science ®Google Scholar
• Blum JS, Wearsch PA, Cresswell P. Pathways of antigen processing. Annu Rev Immunol. 2013;31(1):443–73. doi:10.1146/annurev-immunol-032712-095910.
   PubMed Web of Science ®Google Scholar
• Trolle T, McMurtrey CP, Sidney J, Bardet W, Osborn SC, Kaever T, Sette A, Hildebrand WH, Nielsen M, Peters B. et al. The length distribution of class I–restricted T cell epitopes is determined by both peptide supply and MHC allele–specific binding preference. J Immunol. 2016;196(4):1480–87. doi:10.4049/jimmunol.1501721.
   PubMed Web of Science ®Google Scholar